Literature DB >> 22122984

Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array.

Geoffrey S Baird1, Sally K Nelson, Tracy R Keeney, Alex Stewart, Stephen Williams, Stephan Kraemer, Elaine R Peskind, Thomas J Montine.   

Abstract

An important precondition for the successful development of diagnostic assays of cerebrospinal fluid (CSF) biomarkers of age-related neurodegenerative diseases is an understanding of the dynamic nature of the CSF proteome during the normal aging process. In this study, a novel proteomic technology was used to quantify hundreds of proteins simultaneously in the CSF from 90 cognitively normal adults 21 to 85 years of age. SomaLogic's highly multiplexed proteomic platform can measure more than 800 proteins simultaneously from small volumes of biological fluids using novel slow off-rate modified aptamer (SOMAmer) protein affinity reagents with sensitivity, specificity, and dynamic ranges that meet or exceed those of enzyme-linked immunosorbent assays. In the first application of this technology to CSF, we detected 248 proteins that possessed signals greater than twofold over background. Several novel correlations between detected protein concentrations and age were discovered that indicate that both inflammation and response to injury in the central nervous system may increase with age. Applying this powerful proteomic approach to CSF provides potential new insight into the aging of the human central nervous system that may have utility in discovering new disease-related changes in the CSF proteome.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122984      PMCID: PMC3349859          DOI: 10.1016/j.ajpath.2011.10.024

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

Review 1.  Cytokines and cognition--the case for a head-to-toe inflammatory paradigm.

Authors:  Craig J Wilson; Caleb E Finch; Harvey J Cohen
Journal:  J Am Geriatr Soc       Date:  2002-12       Impact factor: 5.562

2.  Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS.

Authors:  Brett R Wenner; Mark A Lovell; Bert C Lynn
Journal:  J Proteome Res       Date:  2004 Jan-Feb       Impact factor: 4.466

3.  Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis.

Authors:  Sandra Ebert; David J Phillips; Peter Jenzewski; Roland Nau; Anne E O'Connor; Uwe Michel
Journal:  J Neurol Sci       Date:  2006-08-22       Impact factor: 3.181

4.  Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid.

Authors:  Jing Zhang; David R Goodlett; Elaine R Peskind; Joseph F Quinn; Yong Zhou; Qin Wang; Catherine Pan; Eugene Yi; Jimmy Eng; Ruedi H Aebersold; Thomas J Montine
Journal:  Neurobiol Aging       Date:  2005-02       Impact factor: 4.673

5.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Authors:  Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

6.  Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry.

Authors:  Giuseppina Maccarrone; Dale Milfay; Isabel Birg; Marcus Rosenhagen; Florian Holsboer; Rudolf Grimm; Jerome Bailey; Nina Zolotarjova; Christoph W Turck
Journal:  Electrophoresis       Date:  2004-07       Impact factor: 3.535

7.  Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.

Authors:  Roberto Garcia-Navarrete; Esperanza Garcia; Oscar Arrieta; Julio Sotelo
Journal:  J Neurooncol       Date:  2009-10-25       Impact factor: 4.130

8.  Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R Press; M Pashenkov; J P Jin; H Link
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

Review 9.  Brain biopsy in dementia.

Authors:  J D Warren; J M Schott; N C Fox; M Thom; T Revesz; J L Holton; F Scaravilli; D G T Thomas; G T Plant; P Rudge; M N Rossor
Journal:  Brain       Date:  2005-05-18       Impact factor: 13.501

10.  Aptamer-based multiplexed proteomic technology for biomarker discovery.

Authors:  Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

View more
  31 in total

1.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

2.  Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.

Authors:  Carrie M Nielson; Jack Wiedrick; Jian Shen; Jon Jacobs; Erin S Baker; Aaron Baraff; Paul Piehowski; Christine G Lee; Arie Baratt; Vladislav Petyuk; Shannon McWeeney; Jeong Youn Lim; Douglas C Bauer; Nancy E Lane; Peggy M Cawthon; Richard D Smith; Jodi Lapidus; Eric S Orwoll
Journal:  J Bone Miner Res       Date:  2017-04-06       Impact factor: 6.741

Review 3.  Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Authors:  Bibiana Bielekova; Michael R Pranzatelli
Journal:  Semin Pediatr Neurol       Date:  2017-08-12       Impact factor: 1.636

Review 4.  Unbiased approaches to biomarker discovery in neurodegenerative diseases.

Authors:  Alice S Chen-Plotkin
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

Review 5.  Ageing, neurodegeneration and brain rejuvenation.

Authors:  Tony Wyss-Coray
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

6.  Proteomic Analysis of Brain and Cerebrospinal Fluid from the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Potential Biomarkers.

Authors:  David E Sleat; Abla Tannous; Istvan Sohar; Jennifer A Wiseman; Haiyan Zheng; Meiqian Qian; Caifeng Zhao; Winnie Xin; Rosemary Barone; Katherine B Sims; Dirk F Moore; Peter Lobel
Journal:  J Proteome Res       Date:  2017-08-28       Impact factor: 4.466

Review 7.  Measuring biological age using omics data.

Authors:  Jarod Rutledge; Hamilton Oh; Tony Wyss-Coray
Journal:  Nat Rev Genet       Date:  2022-06-17       Impact factor: 53.242

Review 8.  Emerging Proteomic Technologies Provide Enormous and Underutilized Potential for Brain Cancer Research.

Authors:  Qiang Tian; Vineet Sangar; Nathan D Price
Journal:  Mol Cell Proteomics       Date:  2015-09-25       Impact factor: 5.911

9.  Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways.

Authors:  Jordan Bryan; Arpita Mandan; Gauri Kamat; W Kirby Gottschalk; Alexandra Badea; Kendra J Adams; J Will Thompson; Carol A Colton; Sayan Mukherjee; Michael W Lutz
Journal:  Alzheimers Dement       Date:  2021-01-21       Impact factor: 21.566

10.  Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease.

Authors:  Justin McKetney; Daniel J Panyard; Sterling C Johnson; Cynthia M Carlsson; Corinne D Engelman; Joshua J Coon
Journal:  Proteomics Clin Appl       Date:  2021-04-26       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.